King-Jones Heidy
See Remarks
King-Jones Heidy has filed 2 SEC Form 4 filings (13 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Oct 3, 2026.
On the most recent filing, King-Jones Heidy is listed as See Remarks at Spyre Therapeutics, Inc. Inside the rolling window, King-Jones Heidy reported no open-market purchases and 3 open-market sales totaling $5.1M in SYRE. The largest disclosed transaction in the window is a sale of 28,933 SYRE shares on Oct 1, 2026, worth $2.6M.
Companies traded
Other insiders at SYRE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$5.1M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has King-Jones Heidy made?
King-Jones Heidy has filed 2 SEC Form 4 filings (13 transaction rows) across 1 company since 2026.
Which companies does King-Jones Heidy trade?
King-Jones Heidy has filed SEC Form 4 disclosures for 1 company, including SYRE.
When was King-Jones Heidy's most recent SEC Form 4 filing?
King-Jones Heidy's most recent SEC Form 4 filing on Tracefour is dated Oct 3, 2026.
What is King-Jones Heidy's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, King-Jones Heidy is listed as See Remarks.
What is King-Jones Heidy's total buy and sell value in the current window?
Inside the rolling retention window, King-Jones Heidy bought $0 and sold $5.1M based on SEC Form 4 filings.
What was King-Jones Heidy's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 28,933 SYRE shares on 2026-10-01, worth $2.6M, per SEC Form 4 filings.